SEL-120 clinical trials
How each study uses SEL-120 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the SEL-120 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
8 studies that test it; most in 2024 (4)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2021 | 1 |
| 2024 | 4 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 1
Ryvu Therapeutics SA (6) · GCP-Service International West GmbH (1) · Bożenna Dembowska Bagińska (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test SEL-120.
- Dec 2026RVU120 Rollover StudyPhase 2 · Ryvu Therapeutics SA
- Aug 2027Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AMLPhase 2 · Ryvu Therapeutics SA
Studies
Open first, then newest update. How each study uses SEL-120 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- Study of CDK8 Inhibitor RVU120 in Combination With Everolimus in Children With Recurrent or Progressive Group 3 or 4 MedulloblastomaNot yet recruitingPhase 1Bożenna Dembowska BagińskaNCT07865130Written as RVU120
- Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AMLRecruitingPhase 2Ryvu Therapeutics SANCT06191263Written as RVU120
- RVU120 Rollover StudyEnrolling by invitationPhase 2Ryvu Therapeutics SANCT06987058Written as RVU120
- RVU120 (SEL120) in Patients With Relapse/Refractory Metastatic or Advanced Solid TumorsTerminatedPhase 1/2Ryvu Therapeutics SANCT05052255Written as RVU120
- RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic SyndromeTerminatedPhase 1Ryvu Therapeutics SANCT04021368Written as RVU120(SEL120)
- Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AMLTerminatedPhase 2Ryvu Therapeutics SANCT06268574Written as RVU120
- RVU120 in Patients With Intermediate or High-risk, Primary or Secondary MyelofibrosisTerminatedPhase 2Ryvu Therapeutics SANCT06397313Written as RVU120
- RVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic NeoplasmsActive, not recruitingPhase 2GCP-Service International West GmbHNCT06243458Written as RVU120 (SEL120)
Codes
What other systems call SEL-120 · ClinicalTrials.gg INT017900
- UNII (FDA) SDM3M518PJSEL-120One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | SDM3M518PJ | SEL-120 | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.